Surufatinib in G3 Neuroendocrine Tumors
NCT05973968
·
clinicaltrials.gov ↗
UNKNOWN
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumor Grade 3
Interventions
DRUG:
Surufatinib
Sponsor
Qilu Hospital of Shandong University
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]